Home » Stocks » ACHV

Achieve Life Sciences, Inc. (ACHV)

Stock Price: $9.30 USD 0.21 (2.26%)
Updated Jan 15, 2021 12:30 PM EST - Market open
Market Cap 55.69M
Revenue (ttm) n/a
Net Income (ttm) -13.20M
Shares Out 3.29M
EPS (ttm) -7.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $9.30
Previous Close $9.09
Change ($) 0.21
Change (%) 2.26%
Day's Open 9.10
Day's Range 9.14 - 9.45
Day's Volume 166,820
52-Week Range 4.60 - 13.94

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Accesswire - 1 week ago

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commer...

PRNewsWire - 1 month ago

SEATTLE and VANCOUVER, B.C., Dec. 7, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercial...

PRNewsWire - 1 month ago

SEATTLE and VANCOUVER, B.C., Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercial...

PRNewsWire - 1 month ago

SEATTLE and VANCOUVER, BC, Nov. 30, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commerciali...

Seeking Alpha - 2 months ago

Achieve Life Sciences, Inc. (ACHV) CEO John Bencich on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 2 months ago

SEATTLE and VANCOUVER, BC, Oct. 29, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commerciali...

PRNewsWire - 2 months ago

SEATTLE and VANCOUVER, BC, Oct. 27, 2020 /PRNewswire/ --Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercializ...

PRNewsWire - 3 months ago

SEATTLE and VANCOUVER, B.C., Oct. 7, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercial...

PRNewsWire - 3 months ago

SEATTLE and VANCOUVER, BC, Sept. 18, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercial...

PRNewsWire - 3 months ago

SEATTLE, and VANCOUVER, British Columbia, Sept. 18, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development...

PRNewsWire - 4 months ago

SEATTLE and VANCOUVER, BC, Sept. 10, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc.

PRNewsWire - 4 months ago

SEATTLE and VANCOUVER, BC, Sept. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc.

Seeking Alpha - 5 months ago

Achieve Life Sciences, Inc. (ACHV) CEO Richard Stewart on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 5 months ago

SEATTLE and VANCOUVER, British Columbia, Aug. 6, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc.

PRNewsWire - 5 months ago

SEATTLE and VANCOUVER, British Columbia, July 31, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development a...

PRNewsWire - 5 months ago

SEATTLE and VANCOUVER, British Columbia, July 28, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development a...

PRNewsWire - 6 months ago

SEATTLE and VANCOUVER, BC, June 29, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commerciali...

Seeking Alpha - 8 months ago

Achieve Life Sciences, Inc. (ACHV) CEO Richard Stewart on Q1 2020 Results - Earnings Call Transcript

PRNewsWire - 8 months ago

SEATTLE and VANCOUVER, British Columbia, May 14, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development an...

Seeking Alpha - 10 months ago

Achieve Life Sciences, Inc.'s (ACHV) CEO Richard Stewart on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Achieve Life Sciences, Inc. (ACHV) CEO Rick Stewart on Q3 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Achieve Life Sciences, Inc. (ACHV) CEO Rick Stewart on Q2 2019 Results - Earnings Call Transcript

Benzinga - 1 year ago

Shares of thinly traded, nano-cap biotech Achieve Life Sciences Inc (NASDAQ: ACHV) traded sharply higher Friday morning before paring those gains.

Benzinga - 1 year ago

Achieve Life Sciences Inc a company focused on nicotine addiction, announced positive results Tuesday from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation.

Seeking Alpha - 1 year ago

Achieve Life Sciences, Inc. (ACHV) CEO Rick Stewart on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

Achieve Life Sciences, Inc. (ACHV) CEO Richard Stewart on Q4 2018 Results - Earnings Call Transcript

About ACHV

Achieve Life Sciences, a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation aids in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Industry
Biotechnology
CEO
Richard Stewart
Employees
14
Stock Exchange
NASDAQ
Ticker Symbol
ACHV
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ACHV stock is "Buy." The 12-month stock price forecast is 45.00, which is an increase of 384.13% from the latest price.

Price Target
$45.00
(384.13% upside)
Analyst Consensus: Buy